Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 24-Sep-24 4:01 PM View:  | Nippon Shinyaku Co Ltd 10% Owner | Nile Therapeutics, Inc (CAPR) | 20-Sep-24 | Purchase | 2,798,510 | $5.36 | $15,000,000.00 | 65% 4.29M to 7.09M | |
| 09-Aug-24 9:00 AM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 07-Aug-24 | Option Exercise | 34,000 | $1.39 | $47,260.00 | 62% 54.79K to 88.79K | |
| 24-Apr-24 1:30 PM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 23-Apr-24 | Option Exercise | 16,156 | $1.39 | $22,456.80 | 42% 38.63K to 54.79K | |
| 25-Apr-24 9:15 AM View: | Collier Earl M Jr Director | Nile Therapeutics, Inc (CAPR) | 23-Apr-24 | Option Exercise | 30,000 | $1.39 | $41,700.00 | 112% 26.86K to 56.86K | |
| 24-Oct-23 9:25 AM View: | Bergmann Anthony Chief Financial Officer | Nile Therapeutics, Inc (CAPR) | 23-Oct-23 | Option Exercise | 2,178 | $1.39 | $3,027.42 | 1073% 0.2K to 2.38K | |
| 13-Oct-23 1:59 PM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 12-Oct-23 | Private Purchase | 410 | $2.75 | $1,127.50 | 1% 38.22K to 38.63K | |
| 12-Oct-23 9:15 AM View: | Collier Earl M Jr Director | Nile Therapeutics, Inc (CAPR) | 10-Oct-23 | Market Purchase | 10,000 | $2.83 | $28,300.00 | 59% 16.86K to 26.86K | 8% |
| 11-Oct-23 9:15 AM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 09-Oct-23 | Market Purchase | 5,083 | $2.82 | $14,334.10 | 15% 33.14K to 38.22K | 9% |
| 10-Oct-23 9:15 AM View: | Auwaerter Paul Gisbert Director | Nile Therapeutics, Inc (CAPR) | 06-Oct-23 | Market Purchase | 5,000 | $2.84 | $14,200.00 | 100% 0 to 5.0K | 8% |
| 06-Oct-23 9:15 AM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 04-Oct-23 | Market Purchase | 2,500 | $2.90 | $7,250.00 | 8% 30.64K to 33.14K | 6% |
| 16-Aug-23 5:00 PM View: | Litvack Frank Director | Nile Therapeutics, Inc (CAPR) | 14-Aug-23 | Option Exercise | 20,748 | $1.39 | $28,839.70 | 18% 116.89K to 137.63K | |
| 16-Aug-23 5:00 PM View: | Litvack Frank Director | Nile Therapeutics, Inc (CAPR) | 14-Aug-23 | Payment of Exercise | 4,364 | $6.61 | $28,846.00 | (3%) 137.63K to 133.27K | |
| 16-May-23 7:00 PM View: | Marban Linda Chief Executive Officer Director | Nile Therapeutics, Inc (CAPR) | 12-May-23 | Option Exercise | 20,749 | $1.39 | $28,841.10 | 12% 177.85K to 198.6K | |
| 27-Apr-23 5:28 PM View: | Avat Xavier | Nile Therapeutics, Inc (CAPR) | 17-Apr-23 | Private Sale | 14,772 | $64,258.00 | $949,219,008.00 | (100%) 14.77K to 0 | |
| 07-Apr-23 5:00 PM View: | Avat Xavier | Nile Therapeutics, Inc (CAPR) | 05-Apr-23 | Payment of Exercise | 70,019 | $4.19 | $293,380.00 | (83%) 84.79K to 14.77K | |
| 07-Apr-23 5:00 PM View: | Avat Xavier | Nile Therapeutics, Inc (CAPR) | 05-Apr-23 | Option Exercise | 84,791 | $3.46 | $293,377.00 | 100% 0 to 84.79K | |
| 07-Apr-23 5:00 PM View: | Avat Xavier | Nile Therapeutics, Inc (CAPR) | 28-Mar-23 | Private Option Sale | 3,000 | $4.06 | $12,180.00 | (100%) 3.0K to 0 | |
| 23-Feb-23 9:00 AM View: | Litvack Frank Director | Nile Therapeutics, Inc (CAPR) | 21-Feb-23 | Option Exercise | 14,027 | $1.39 | $19,497.50 | 11% 127.77K to 141.8K | |
| 23-Feb-23 9:00 AM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 21-Feb-23 | Disposition | 452 | $4.31 | $1,948.12 | (< 1%) 62.6K to 62.15K | |
| 23-Feb-23 9:00 AM View: | Litvack Frank Director | Nile Therapeutics, Inc (CAPR) | 21-Feb-23 | Payment of Exercise | 4,524 | $4.31 | $19,498.40 | (3%) 141.8K to 137.28K | |
| 23-Feb-23 9:00 AM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 21-Feb-23 | Option Exercise | 1,401 | $1.39 | $1,947.39 | 2% 61.2K to 62.6K | |
| 15-Feb-23 8:00 PM View: | Collier Earl M Jr Director | Nile Therapeutics, Inc (CAPR) | 14-Feb-23 | Option Exercise | 1,401 | $1.39 | $1,947.39 | 9% 15.46K to 16.86K | |
| 15-Feb-23 8:00 PM View: | Dunbar George W Jr Director | Nile Therapeutics, Inc (CAPR) | 14-Feb-23 | Option Exercise | 1,401 | $1.39 | $1,947.39 | 15% 9.15K to 10.56K | |
| 04-Nov-22 9:25 AM View: | Krasney Karen EVP, General Counsel | Nile Therapeutics, Inc (CAPR) | 03-Nov-22 | Option Exercise | 18,932 | $1.39 | $26,315.50 | 1698% 1.11K to 20.05K | |
| 07-Jul-22 5:31 PM View: | Avat Xavier CHIEF BUSINESS OFFICER | Nile Therapeutics, Inc (CAPR) | 06-Jul-22 | Purchase | 1,000 | $3.68 | $3,680.00 | 50% 2.0K to 3.0K | |
| 01-Jul-22 9:00 PM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 30-Jun-22 | Option Exercise | 10,796 | $1.39 | $15,006.40 | 54% 19.84K to 30.64K | |
| 07-Jul-22 5:31 PM View: | Avat Xavier CHIEF BUSINESS OFFICER | Nile Therapeutics, Inc (CAPR) | 29-Jun-22 | Purchase | 1,500 | $3.76 | $5,642.85 | 300% 0.5K to 2.0K | |
| 01-Jul-22 9:00 PM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 29-Jun-22 | Private Option Sale | 10,796 | $3.77 | $40,700.90 | (22%) 48.06K to 37.26K | |
| 01-Jul-22 9:00 PM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 29-Jun-22 | Sale | 17,419 | $3.77 | $65,669.60 | (47%) 37.26K to 19.84K | |
| 29-Jun-22 9:00 PM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 27-Jun-22 | Private Sale | 17,775 | $4.44 | $78,921.00 | (27%) 65.83K to 48.06K | |
| 01-Apr-22 5:00 PM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 31-Mar-22 | Payment of Exercise | 11,309 | $3.43 | $38,789.90 | (41%) 27.9K to 16.59K | |
| 01-Apr-22 5:00 PM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 31-Mar-22 | Option Exercise | 27,904 | $1.39 | $38,786.60 | 100% 0 to 27.9K | |
| 31-Mar-22 5:00 PM View: | Dunbar George W Jr Director | Nile Therapeutics, Inc (CAPR) | 29-Mar-22 | Payment of Exercise | 6,300 | $3.41 | $21,483.00 | (41%) 15.46K to 9.15K | |
| 31-Mar-22 5:00 PM View: | Dunbar George W Jr Director | Nile Therapeutics, Inc (CAPR) | 29-Mar-22 | Option Exercise | 15,455 | $1.39 | $21,482.40 | 100% 0 to 15.46K | |
| 09-Mar-22 7:00 PM View: | Collier Earl M Jr Director | Nile Therapeutics, Inc (CAPR) | 08-Mar-22 | Option Exercise | 15,455 | $1.39 | $21,482.40 | 100% 0 to 15.46K | |
| 04-Jan-22 9:01 PM View: | Litvack Frank Director | Nile Therapeutics, Inc (CAPR) | 03-Jan-22 | Option Exercise | 154,543 | $1.39 | $214,815.00 | 758% 20.39K to 174.93K | |
| 04-Jan-22 9:01 PM View: | Litvack Frank Director | Nile Therapeutics, Inc (CAPR) | 03-Jan-22 | Payment of Exercise | 67,552 | $3.18 | $214,815.00 | (39%) 174.93K to 107.38K | |
| 29-Dec-21 9:00 AM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 27-Dec-21 | Option Exercise | 35,846 | $1.23 | $43,912.60 | 120% 29.99K to 65.83K | |
| 28-Sep-20 8:30 AM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 24-Sep-20 | Option Exercise | 8,299 | $3.70 | $30,706.30 | 8% 100.12K to 108.42K | (2%) |
| 29-Jul-20 6:39 PM View: | Marban Linda Chief Executive Officer Director | Nile Therapeutics, Inc (CAPR) | 27-Jul-20 | Option Exercise | 41,497 | $3.70 | $153,539.00 | 13% 330.79K to 372.28K | (2%) |
| 29-Jul-20 6:39 PM View: | Marban Linda Chief Executive Officer Director | Nile Therapeutics, Inc (CAPR) | 27-Jul-20 | Payment of Exercise | 15,652 | $9.81 | $153,546.00 | (4%) 372.28K to 356.63K | 61% |
| 19-Dec-19 7:34 PM View: | Musket David B Director | Nile Therapeutics, Inc (CAPR) | 17-Dec-19 | Grant | 20,391 | -- | -- | 212% 9.6K to 29.99K | |
| 19-Dec-19 7:35 PM View: | Litvack Frank Director | Nile Therapeutics, Inc (CAPR) | 17-Dec-19 | Grant | 20,391 | -- | -- | 100% 0 to 20.39K | |
| 19-Dec-19 7:34 PM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 17-Dec-19 | Grant | 20,391 | -- | -- | 26% 79.73K to 100.12K | |
| 14-Feb-18 10:00 PM View: | Kazam Joshoa A Director | Nile Therapeutics, Inc (CAPR) | 27-Dec-17 | Gift | 17,786 | -- | -- | (34%) 52.67K to 34.88K | |
| 14-Feb-18 10:00 PM View: | Kazam Joshoa A Director | Nile Therapeutics, Inc (CAPR) | 26-Dec-17 | Gift | 1,000 | -- | -- | (2%) 53.67K to 52.67K | |
| 04-Jan-18 5:05 PM View: | Smith Rachel Vice President of R&D | Nile Therapeutics, Inc (CAPR) | 22-Dec-17 | Payment of Exercise | 2,244 | $1.48 | $3,321.12 | (11%) 20.75K to 18.5K | 72% |
| 04-Jan-18 5:05 PM View: | Smith Rachel Vice President of R&D | Nile Therapeutics, Inc (CAPR) | 22-Dec-17 | Option Exercise | 20,748 | $0.16 | $3,319.68 | 100% 0 to 20.75K | |
| 25-Oct-17 12:00 PM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 23-Oct-17 | Option Exercise | 20,748 | $0.16 | $3,319.68 | 3% 776.54K to 797.29K | |
| 11-May-17 2:31 PM View: | Manzo Louis Director | Nile Therapeutics, Inc (CAPR) | 09-May-17 | Market Purchase | 10,000 | $3.10 | $31,000.00 | 1% 766.54K to 776.54K | (87%) |
